{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.4","upperLimit":"99.5","value":"80.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Overall response rate (ORR) determined by Investigator assessment after JCAR017 infusion. The ORR is the percent of participants with best overall response (BOR) of either complete response (CR), complete response unconfirmed (Cru) or partial response (PR).\n\nComplete response (CR):\n\n* Brain imaging: No contrast enhancement\n* Corticosteroid dose: None\n* Eye examination: Normal\n* Cerebrospinal fluid cytology: Negative\n\nComplete response unconfirmed (CRu):\n\n* Brain imaging: No contrast enhancement, Minimal abnormality\n* Corticosteroid dose: Any\n* Eye examination: Normal, minor RPE abnormality\n* Cerebrospinal fluid cytology: Negative\n\nPartial response (PR):\n\n* Brain imaging: 50% decrease in enhancing tumor, no contrast enhancement.\n* Corticosteroid dose: Irrelevant\n* Eye examination: Minor RPE abnormality, decrease in vitreous cells or retinal infiltrate.\n* Cerebrospinal fluid cytology: Negative, persistent or suspicious","dispersionType":"95% Confidence Interval","groups":[{"description":"JCAR017 was infused at a dose of 100 x 10\\^6 JCAR017-positive transfected viable T cells (50 × 10\\^6 CD8+ CAR+ T cells and 50 × 10\\^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of Lymphodepleting chemotherapy).","id":"OG000","title":"Cohort 5: Primary Central Nervous System Lymphoma"}],"paramType":"NUMBER","populationDescription":"All participants in the JCAR017 treated set. Prespecified to be reported for cohort 5 only.","reportingStatus":"POSTED","timeFrame":"From JCAR017 infusion until disease progression, end of study, the start of another anticancer therapy, or hemopoietic stem cell transplant (HSCT) (up to approximately 63 months)","title":"Overall Response Rate (ORR) Per Investigator in Cohort 5","type":"PRIMARY","unitOfMeasure":"Percent of Participants"}